Riskpilot← Back to searchSign inGet full accessMathias Walden Diagnostics AB
ABActiveOrg 5592356124Viltstigen 2Medical specialists activities · NACE 8622Est. 20200 employees
Revenue 2025
SEK 7K
-90% vs 2024
EBITDA margin
-12.6%
-103% vs 2024
Equity ratio
99.3%
Financial strength
Net profit 2025
SEK -74
-100% vs 2024
| Revenue | SEK 7K | -90% |
| EBITDA | SEK -936 | -103% |
| Net profit | SEK -74 | -100% |
| Total assets | SEK 147K | +0% |
| Equity | SEK 146K | +0% |
| Employees | 0 | — |
Legal name
Mathias Walden Diagnostics AB
Org number
5592356124
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
8 januari 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-04-30
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamoten suppleanten
Company purpose
Bolaget ska bedriva medicinsk konsultation, konsultverksamhet inom organisationsstyrning, ägar- och ledningsfrågor, äga och förvalta fast egendom, aktier och värdepapper samt bedriva därmed förenlig verksamhet.
Address
Viltstigen 2
Email
agneta@waldenkonsult.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | 285 | 138 | 76 | 7 |
| Staff expenses | — | — | −1 | −0 | −0 |
| EBITDA | 0 | 205 | 71 | 36 | −1 |
| Depreciation & amort. | — | −0 | — | — | — |
| EBIT | 0 | 205 | 71 | 36 | −1 |
| Net financials | — | — | −1 | 1 | 1 |
| Profit before tax | 0 | 204 | 70 | 36 | −0 |
| Tax | — | −42 | −14 | −7 | — |
| Net profit | — | 162 | 55 | 29 | −0 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | — | 361 | 126 | 147 | 147 |
| Equity | — | 248 | 117 | 146 | 146 |
| Long-term debt | — | 0 | — | — | — |
| Short-term debt | — | 112 | 10 | 1 | 1 |
| Total debt | — | 112 | 10 | 1 | 1 |
EBITDA margin
-12.6%
This company
15.8%
Market median
-180% vs market
20212025
Equity ratio
99.3%
This company
38.2%
Market median
+160% vs market
20212025
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20212025
Net profit margin
-1.0%
This company
8.1%
Market median
-112% vs market
20212025
Asset turnover
0.05×
This company
1.12×
Market median
-96% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-05-01 – 2025-04-30
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-05-01 – 2024-04-30
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-05-01 – 2023-04-30
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-05-01 – 2022-04-30
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-01-01 – 2021-04-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PM Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2025 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Deputy Board Member | 2025 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Mathias Walden Diagnostics AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Philip Mathias Waldén | Chief Executive Officer | 0 companies |
| Agneta Waldén | Board of Directors | 0 companies |
| Bita Fakhri Waldén | Deputy Board Member | 0 companies |
| Nils Philip Waldén | Deputy Board Member | 0 companies |